Based on 4 analysts giving stock ratings to Bolt Biotherapeutics Inc in the past month.
In the current month, BOLT has received 2 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BOLT average Analyst price target in the last month is 75.000.
Based on analysts' estimates, BOLT EPS is projected to reach -3.850 in FY2026Q4, following reported EPS of -2.249 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -2.25, while Bolt Biotherapeutics IncBOLT's earnings per share (EPS) for the previous quarter was USD -4.57. EPS for the next quarter is expected at USD -3.85.